Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NASDAQ:NTLA) has initiated HAELO, a global Phase 3 study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema (HAE). NTLA-2002 is designed as a single-dose treatment to prevent potentially life-threatening swelling attacks in HAE patients. The study will evaluate the efficacy and safety of NTLA-2002 in 60 adults with Type I or Type II HAE, with patients randomized 2:1 to receive a single 50 mg infusion of NTLA-2002 or placebo.

The primary endpoint is the change in number of HAE attacks from week 5 through week 28. This initiation follows positive safety and efficacy data from the ongoing Phase 1/2 study, which showed dramatic reductions in attack rate and consistent, deep, and durable reductions in kallikrein levels. Detailed results from the Phase 2 portion will be presented at the 2024 ACAAI Annual Scientific Meeting in October.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on CRISPR-based therapies, has announced the granting of inducement awards to nine new employees under its 2024 Inducement Plan. The awards, granted on October 1, 2024, consist of time-based restricted stock units (RSUs) for 54,944 shares of Intellia's common stock.

The RSUs will vest in three equal installments on October 1 of 2025, 2026, and 2027, subject to the employees' continued service. These awards were granted outside of Intellia's stockholder-approved equity incentive plans, as part of the 2024 Inducement Plan adopted by the board of directors in June 2024. The compensation committee approved the awards as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) announced that new interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z) will be presented at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed as a single-dose treatment for transthyretin (ATTR) amyloidosis.

The presentation will include safety data, reduction in serum TTR, biomarkers of disease progression, and functional capacity data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Dr. Marianna Fontana from University College London will present the findings on November 16, 2024, as part of the Late-Breaking Science session.

Intellia is developing nex-z in collaboration with Regeneron as part of a multi-target discovery, development, and commercialization partnership.

Intellia Therapeutics (NASDAQ:NTLA) has announced that detailed results from the Phase 2 study of NTLA-2002, their investigational in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE), will be presented at the 2024 ACAAI Annual Scientific Meeting. The presentation, titled "Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema," will take place on October 26, 2024. This follows a previous positive topline announcement that the study met its primary and all secondary endpoints. Intellia will also host an investor webcast on October 28, 2024, to review the new data.

Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company, has announced inducement grants for five new employees under its 2024 Inducement Plan. The grants include:

• Non-qualified stock options for 49,751 shares
• Time-based RSUs for 44,154 shares
• Performance-based RSUs for 17,064 shares linked to total stockholder return
• Performance-based RSUs for 12,500 shares tied to development milestones

These equity awards, granted outside of Intellia's stockholder-approved plans, were approved by the compensation committee as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) reported positive Phase 2 results for NTLA-2002 in hereditary angioedema (HAE), meeting primary and secondary endpoints. The company plans to initiate a Phase 3 trial in 2H 2024 with the selected 50 mg dose. Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis with cardiomyopathy. Intellia expects to dose the first patient in the Phase 1/2 study of NTLA-3001 for alpha-1 antitrypsin deficiency in 2H 2024. The company ended Q2 2024 with $939.9 million in cash, expected to fund operations into late 2026. Q2 financial results show collaboration revenue of $7.0 million, R&D expenses of $114.2 million, and a net loss of $147.0 million.

Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on CRISPR-based therapies, has announced its upcoming second quarter 2024 earnings call. The conference call is scheduled for August 8, 2024, at 8 a.m. ET. During this call, the company will present its Q2 2024 financial results and provide operational highlights.

Investors and interested parties can join the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available. A replay of the call will be accessible through Intellia's website after 12 p.m. ET on the same day.

Intellia Therapeutics (NASDAQ:NTLA) has received authorization from the UK's MHRA to initiate a Phase 1/2 clinical trial for NTLA-3001, a potential one-time CRISPR-based gene editing treatment for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. NTLA-3001 aims to normalize AAT protein levels by inserting a healthy copy of the SERPINA1 gene, potentially halting disease progression and eliminating the need for weekly infusions or lung transplants.

The study will enroll up to 30 adult patients and evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics. Intellia plans to dose the first patient in the second half of 2024. This trial marks Intellia's first wholly owned in vivo targeted gene insertion candidate to enter clinical stages, validating their modular gene insertion platform for addressing various protein deficiency diseases.

Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company, has announced inducement grants for its new Executive Vice President and Chief Financial Officer, Edward Dulac. The grants, awarded on July 22, 2024, include:

96,219 non-qualified stock options with an exercise price of $25.33 per share, vesting over three years; 66,324 time-based restricted stock units (RSUs) vesting annually over three years; 33,162 performance-based RSUs tied to total stockholder return over three years; and 30,000 performance-based RSUs (at target) linked to development milestones over three years.

These grants were made outside of Intellia's stockholder-approved equity incentive plans, under the 2024 Inducement Plan adopted in June 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).